68 related articles for article (PubMed ID: 20510208)
1. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray.
Morse DL; Balagurunathan Y; Hostetter G; Trissal M; Tafreshi NK; Burke N; Lloyd M; Enkemann S; Coppola D; Hruby VJ; Gillies RJ; Han H
Biochem Pharmacol; 2010 Sep; 80(5):748-54. PubMed ID: 20510208
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology.
Iacobuzio-Donahue CA; Maitra A; Shen-Ong GL; van Heek T; Ashfaq R; Meyer R; Walter K; Berg K; Hollingsworth MA; Cameron JL; Yeo CJ; Kern SE; Goggins M; Hruban RH
Am J Pathol; 2002 Apr; 160(4):1239-49. PubMed ID: 11943709
[TBL] [Abstract][Full Text] [Related]
3. The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy.
Nurmi AM; Hagström J; Mustonen H; Seppänen H; Haglund C
PLoS One; 2022; 17(5):e0267792. PubMed ID: 35536778
[TBL] [Abstract][Full Text] [Related]
4. Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy.
Roacho-Pérez JA; Garza-Treviño EN; Delgado-Gonzalez P; G-Buentello Z; Delgado-Gallegos JL; Chapa-Gonzalez C; Sánchez-Domínguez M; Sánchez-Domínguez CN; Islas JF
Life (Basel); 2021 Nov; 11(11):. PubMed ID: 34833063
[TBL] [Abstract][Full Text] [Related]
5. Light-Inducible Spatio-Temporal Control of TLR4 and NF-κB-Gluc Reporter in Human Pancreatic Cell Line.
Stierschneider A; Grünstäudl P; Colleselli K; Atzler J; Klein CT; Hundsberger H; Wiesner C
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502140
[TBL] [Abstract][Full Text] [Related]
6. Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling.
Karolak A; Estrella VC; Huynh AS; Chen T; Vagner J; Morse DL; Rejniak KA
Sci Rep; 2018 Feb; 8(1):3638. PubMed ID: 29483578
[TBL] [Abstract][Full Text] [Related]
7. Cell-surface marker discovery for lung cancer.
Cohen AS; Khalil FK; Welsh EA; Schabath MB; Enkemann SA; Davis A; Zhou JM; Boulware DC; Kim J; Haura EB; Morse DL
Oncotarget; 2017 Dec; 8(69):113373-113402. PubMed ID: 29371917
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer.
Słotwiński R; Słotwińska SM
Cent Eur J Immunol; 2016; 41(4):404-418. PubMed ID: 28450804
[TBL] [Abstract][Full Text] [Related]
9. High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.
Leppänen J; Helminen O; Huhta H; Kauppila JH; Isohookana J; Haapasaari KM; Lehenkari P; Saarnio J; Karttunen TJ
Virchows Arch; 2017 Apr; 470(4):401-410. PubMed ID: 28191612
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers and Targeted Therapy in Pancreatic Cancer.
Karandish F; Mallik S
Biomark Cancer; 2016; 8(Suppl 1):27-35. PubMed ID: 27147897
[TBL] [Abstract][Full Text] [Related]
11. Is metastatic pancreatic cancer an untargetable malignancy?
Kourie HR; Gharios J; Elkarak F; Antoun J; Ghosn M
World J Gastrointest Oncol; 2016 Mar; 8(3):297-304. PubMed ID: 26989465
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma.
Chen DT; Davis-Yadley AH; Huang PY; Husain K; Centeno BA; Permuth-Wey J; Pimiento JM; Malafa M
PLoS One; 2015; 10(8):e0133562. PubMed ID: 26247463
[TBL] [Abstract][Full Text] [Related]
13. Gene expression disorders of innate antibacterial signaling pathway in pancreatic cancer patients: implications for leukocyte dysfunction and tumor progression.
Słotwiński R; Dąbrowska A; Lech G; Słodkowski M; Słotwińska SM
Cent Eur J Immunol; 2014; 39(4):498-507. PubMed ID: 26155170
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for pancreatic cancer: recent achievements in proteomics and genomics through classical and multivariate statistical methods.
Marengo E; Robotti E
World J Gastroenterol; 2014 Oct; 20(37):13325-42. PubMed ID: 25309068
[TBL] [Abstract][Full Text] [Related]
15. Intervention on toll-like receptors in pancreatic cancer.
Vaz J; Andersson R
World J Gastroenterol; 2014 May; 20(19):5808-17. PubMed ID: 24914341
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer biomarkers and their implication in cancer diagnosis and epidemiology.
Verma M
Cancers (Basel); 2010 Nov; 2(4):1830-7. PubMed ID: 24281203
[TBL] [Abstract][Full Text] [Related]
17. Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.
Huynh AS; Chung WJ; Cho HI; Moberg VE; Celis E; Morse DL; Vagner J
J Med Chem; 2012 Nov; 55(22):9751-62. PubMed ID: 23098072
[TBL] [Abstract][Full Text] [Related]
18. Analysis of whole genomic expression profiles and screening of the key signaling pathways associated with pancreatic cancer.
He C; Jiang H; Geng S; Sheng H; Shen X; Zhang X; Zhu S; Chen X; Yang C; Gao H
Int J Clin Exp Pathol; 2012; 5(6):537-46. PubMed ID: 22949936
[TBL] [Abstract][Full Text] [Related]
19. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.
Winter JM; Tang LH; Klimstra DS; Brennan MF; Brody JR; Rocha FG; Jia X; Qin LX; D'Angelica MI; DeMatteo RP; Fong Y; Jarnagin WR; O'Reilly EM; Allen PJ
PLoS One; 2012; 7(7):e40157. PubMed ID: 22792233
[TBL] [Abstract][Full Text] [Related]
20. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.
Erkan M; Hausmann S; Michalski CW; Fingerle AA; Dobritz M; Kleeff J; Friess H
Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):454-67. PubMed ID: 22710569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
